Physician profile
Donald Mcnicol
NPI 1912920034
$1,787.53
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,175 · 2022: $613.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.39 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $397.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $241.18 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $170.50 | 2022 | |
| Lilly USA, LLC | $155.69 | 2021-2022 | |
| Novo Nordisk INC | $82.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $66.48 | 2021-2022 | |
| Pfizer INC. | $34.30 | 2021-2022 | |
| Amarin Pharma, INC. | $34.19 | 2021-2022 | |
| Eisai INC. | $26.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.51 | 2021 | |
| Almatica Pharma LLC | $23.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.16 | 2021 | |
| Amgen INC. | $19.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.90 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.84 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.01 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.74 | 2022 | |
| Glaxosmithkline, LLC. | $14.35 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mcnicol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.